Anti-CD70 Antibody Drug Conjugates

Ambrx, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application PCT/US2013/046669, filed Jun 19, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 10,208,123	Anti-CD70 Antibody Drug Conjugates Ambrx, Inc. In force Term ends Jun 19, 2033 · High confidence	Ambrx, Inc.	In force	Term ends Jun 19, 2033	Term ends Jun 19, 2033	High confidence
US 11,459,392	ANTI-CD70 Antibody Drug Conjugates Ambrx, Inc. In force Term ends Jun 19, 2033 · High confidence	Ambrx, Inc.	In force	Term ends Jun 19, 2033	Term ends Jun 19, 2033	High confidence
US 12,037,405	Anti-CD70 Antibody Drug Conjugates Ambrx, Inc. In force Term ends Jun 19, 2033 · Medium confidence	Ambrx, Inc.	In force	Term ends Jun 19, 2033	Term ends Jun 19, 2033	Medium confidence
Application 18/668,300	Anti-CD70 Antibody Drug Conjugates Ambrx, Inc. Pending Not granted	Ambrx, Inc.	Pending	Not granted	not computed

4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

3 of these are in force and held by Ambrx, Inc..

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.